{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:00:02Z","timestamp":1774008002637,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00508-010-1522-y","type":"journal-article","created":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T15:53:36Z","timestamp":1295106816000},"page":"61-64","source":"Crossref","is-referenced-by-count":8,"title":["Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report","Sorafenib bei nicht-resektablem intrahepatischem cholangiozellul\u00e4rem Karzinom: ein Fallbericht"],"prefix":"10.1007","volume":"123","author":[{"given":"Matthias","family":"Pinter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Sieghart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Reisegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Wrba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"1522_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000077991","volume":"66","author":"MJ Olnes","year":"2004","unstructured":"Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004;66:167\u201379","journal-title":"Oncology"},{"key":"1522_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","volume":"234","author":"WR Jarnagin","year":"2001","unstructured":"Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507\u201317; discussion 517\u2013509","journal-title":"Ann Surg"},{"key":"1522_CR3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/MCG.0b013e31802f3132","volume":"41","author":"YH Shaib","year":"2007","unstructured":"Shaib YH, Davila JA, Henderson L, et al. Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study. J Clin Gastroenterol 2007;41:911\u20137","journal-title":"J Clin Gastroenterol"},{"key":"1522_CR4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1245\/s10434-007-9627-x","volume":"15","author":"JC Tan","year":"2008","unstructured":"Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinoma \u2013 a population-based study. Ann Surg Oncol 2008;15:600\u20138","journal-title":"Ann Surg Oncol"},{"key":"1522_CR5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0002-9610(05)80696-8","volume":"166","author":"RM Goldstein","year":"1993","unstructured":"Goldstein RM, Stone M, Tillery GW, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993;166:768\u2013771; discussion 771\u2013762","journal-title":"Am J Surg"},{"key":"1522_CR6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896\u2013902","journal-title":"Br J Cancer"},{"key":"1522_CR7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273\u201381","journal-title":"N Engl J Med"},{"key":"1522_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2","volume":"75","author":"MT Carriaga","year":"1995","unstructured":"Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171\u201390","journal-title":"Cancer"},{"key":"1522_CR9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378\u201390","journal-title":"N Engl J Med"},{"key":"1522_CR10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00508-008-0968-7","volume":"120","author":"H Burgmann","year":"2008","unstructured":"Burgmann H, Janata O, Allerberger F, et al. Hospital antibiotic management in Austria \u2013 results of the ABS maturity survey of the ABS International group. Wien Klin Wochenschr 2008;120:280\u20133","journal-title":"Wien Klin Wochenschr"},{"key":"1522_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00508-009-1295-3","volume":"122","author":"KA Kierner","year":"2010","unstructured":"Kierner KA, Gartner V, Bartsch R, et al. Attitudes towards palliative care in primary metastatic cancer: a survey among oncologists. Wien Klin Wochenschr 2010;122:45\u20139","journal-title":"Wien Klin Wochenschr"},{"key":"1522_CR12","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1158\/1078-0432.CCR-09-0089","volume":"15","author":"K Schmid","year":"2009","unstructured":"Schmid K, Oehl N, Wrba F, et al. EGFR\/KRAS\/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009;15:4554\u201360","journal-title":"Clin Cancer Res"},{"key":"1522_CR13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"Dis","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis;30:52\u201360","journal-title":"Semin Liver"},{"key":"1522_CR14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","volume":"14","author":"M Pinter","year":"2009","unstructured":"Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70\u20136","journal-title":"Oncologist"},{"key":"1522_CR15","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/lt.20034","volume":"10","author":"JM Llovet","year":"2004","unstructured":"Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115\u201320","journal-title":"Liver Transpl"},{"key":"1522_CR16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bcp.2006.12.031","volume":"73","author":"A Huether","year":"2007","unstructured":"Huether A, Hopfner M, Baradari V, et al. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007;73:1308\u201317","journal-title":"Biochem Pharmacol"},{"key":"1522_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12029-008-9028-9","volume":"38","author":"RV LaRocca","year":"2007","unstructured":"LaRocca RV, Hicks MD, Mull L, et al. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. J Gastrointest Cancer 2007;38:154\u20136","journal-title":"J Gastrointest Cancer"},{"key":"1522_CR18","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1200\/jco.2007.25.18_suppl.4639","volume":"25","author":"AB El-Khoueiry","year":"2007","unstructured":"El-Khoueiry AB, Rankin C, Lenz HJ, et al. SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 2007;25:4639:Abstract 4618S","journal-title":"J Clin Oncol"},{"key":"1522_CR19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","volume":"102","author":"C Bengala","year":"2010","unstructured":"Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010;102:68\u201372","journal-title":"Br J Cancer"},{"key":"1522_CR20","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099\u2013109","journal-title":"Cancer Res"},{"key":"1522_CR21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","volume":"52","author":"A Tannapfel","year":"2003","unstructured":"Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706\u201312","journal-title":"Gut"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-010-1522-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1522-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T17:45:59Z","timestamp":1592243159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-010-1522-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":21,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s00508-010-1522-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}